In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmaceutical/Biotechnology Deal Statistics Quarterly, Q3 2009

Executive Summary

Thanks to the return of the initial public offering and a strong market for follow-ons, money from public investors made a huge comeback during the third quarter of 2009. The merger and acquisition scorecard totaled $17.3 billion from 22 transactions--four of which topped the billion-dollar mark. And in alliances, most notable was Johnson & Johnson and Elan Corp. PLC's joint venture, which will acquire all of the assets and rights to Elan's Alzheimer's Immunotherapy Program.
Advertisement

Related Content

Abbott's Solvay Pharma Buy More Salve Than Cure
Will IPOs Come Back? Investors Watching Anthera; Big Pharma Should Too
P&G Kisses Pharma Biz Goodbye In $3.1B Deal With Warner Chilcott
Adamas' Series D Round Brings In $40 Million For Combination Antiviral Against Flu
All You Need Is Data: HGS Seizes The Moment To Raise $357M In Public Offering
Emerging Markets, Acquisitions Prop Up Growth At Sanofi Aventis
Elan's High Wire Act Finds a Semi-Safe Net
Elan's High Wire Act Finds a Semi-Safe Net
Emerging Pharma Markets: Adapt, Diversify, and Persist
Emerging Pharma Markets: Adapt, Diversify, and Persist

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV003223

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel